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Purpose: To facilitate future diagnosis of Knobloch syndrome (KS) and better understand its etiology, we sought to
identify not yet described COL18A1 mutations in KS patients. In addition, we tested whether mutations in this gene lead
to absence of the COL18A1 gene product and attempted to better characterize the functional effect of a previously reported
missense mutation.
Methods: Direct sequencing of COL18A1 exons was performed in KS patients from four unrelated pedigrees. We used
immunofluorescent histochemistry in skin biopsies to evaluate the presence of type XVIII collagen in four KS patients
carrying two already described mutations: c.3277C>T, a nonsense mutation, and c.3601G>A, a missense mutation.
Furthermore, we determined the binding properties of the mutated endostatin domain p.A1381T (c.3601G>A) to
extracellular matrix proteins using ELISA and surface plasmon resonance assays.
Results: We identified four novel mutations in COL18A1, including a large deletion involving exon 41. Skin biopsies
from KS patients revealed lack of type XVIII collagen in epithelial basement membranes and blood vessels. We also found
a reduced affinity of p.A1381T endostatin to some extracellular matrix components.
Conclusions: COL18A1 mutations involved in Knobloch syndrome have a distribution bias toward the coding exons of
the C-terminal end. Large deletions must also be considered when point mutations are not identified in patients with
characteristic KS phenotype. We report, for the first time, lack of type XVIII collagen in KS patients by immunofluorescent
histochemistry in skin biopsy samples. As a final point, we suggest the employment of this technique as a preliminary
and complementary test for diagnosis of KS in cases when mutation screening either does not detect mutations or reveals
mutations of uncertain effect, such as the p.A1381T change.
Knobloch syndrome (KS; OMIM 267750) is an
autosomal recessive disorder characterized by high myopia,
macular abnormalities, vitreoretinal degeneration, retinal
detachment, and occipital encephalocele [1-4]. The spectrum
of clinical variability is not completely known due to the small
number of cases reported in the literature [5]. Most KS cases
are caused by null mutations in the COL18A1 gene
(chr21q22.3), which comprises 43 exons and transcribes three
different isoforms by the use of two promoters and alternative
splicing in the third exon [4,6]. The three encoded collagen
XVIII proteins differ only by their signal peptides and by part
of the N-terminal region of the NC11 domain. The short
isoform (NC11–303) is transcribed from the first promoter,
Correspondence to: Dr. Marita-Rita Passos-Bueno, Centro de
Estudos do Genoma Humano, Instituto de Biociências, Universidade
de São Paulo, Departamento de Genética e  Biologia  Evolutiva,
Rua do Matão, 277, Sala 200, São Paulo, SP  05508-090,  Brazil;
Phone: 55-11-3091-9910; FAX: 55-11-3091-7419;
email: passos@ib.usp.br
upstream of exon 1, and is encoded by exons 1, 2, 4–43. The
intermediate (NC11–493) and long (NC11–728) forms are
transcribed from the second promoter, upstream of exon 3,
and they differ by use of an internal splice site within exon 3.
Collagen XVIII is a component of basement membranes [7];
however, the abundance of its isoforms varies: the short
isoform is predominant in most tissues, including heart,
kidney, retina, and fetal brain, while the intermediate and long
isoforms are highly expressed in the liver [3,4,6]. The C-
terminal domain of type XVIII collagen can be cleaved to
form endostatin, which functions as a potent angiogenesis
inhibitor that influences endothelial cell proliferation,
migration, apoptosis and tubulogenesis [8-11]. Endostatin
binds to several extracellular matrix (ECM) components,
including laminin-1, fibulin-1, fibulin-2, nidogen-2, perlecan,
heparan sulfate, and fibronectin [12-14].
To date, 12 rare mutations have been described in KS
patients with the typical clinical features of the disease [3-5,
15-17]. All mutations, with the exception of a missense
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change (p.A1381T; numbered according to GenBank cDNA
AF018081.1) of still unclear functional effect on the protein
[18,19], are predicted to create premature stop codons. These
mutations possibly lead to a lack of the protein, even though
the complete lack of collagen XVIII has still not been
demonstrated. COL18A1 mutations are distributed along the
gene in regions common to all known isoforms, except for c.
12–2A>T, which only affects the short isoform. The
description of pathogenic mutations in a larger number of KS
patients and further functional analysis of the mutation
p.A1381T may better characterize the spectrum of mutations
along the COL18A1 gene.
Screening the entire gene for mutations is still time
consuming. We have previously shown that endostatin plasma
measurements do not allow a precise diagnosis, as patients
with null mutations had positive levels of this fragment [4],
and no other methods to confirm KS diagnosis were tested.
New strategies that might allow the screening of a larger
number of patients, including those without the full phenotype
of the syndrome, could help delineate the clinical variability.
In the present work we describe four new families with
KS patients and the respective responsible mutations in
COL18A1. Consistent with previous results, we find
heterogeneity for mutation sites leading to this syndrome. We
also assessed the immunohistochemical expression of type
XVIII collagen in skin biopsies of KS patients carrying
nonsense mutations to test the potential of this method as a
screening tool for a larger number of patients. Finally, we
evaluated in situ and in vitro effects of endostatin p.A1381T
by testing skin biopsies for the presence of type XVIII
collagen in KS patients carrying this mutation and evaluating
the binding properties of the mutated endostatin to other ECM
components.
METHODS
COL18A1 mutations analysis: Five KS patients were referred
to the Centro de Estudos do Genoma Humano at the
University of São Paulo. Two were siblings and the other three
were not related. They presented with typical KS phenotypic
characteristics: high myopia detected early in childhood
(usually before 1 year of age) and occipital encephalocele, as
described elsewhere [2,20]. No other alterations were
observed.
We screened for mutations in the COL18A1 gene by
direct sequencing of exons and flanking intronic regions, as
previously described [4]. All mutations were named according
to the nomenclature suggested by den Dunnen and
Antonarakis [21]. The numbering followed the short isoform
(GenBank AF018082.1), except where indicated.
Skin biopsies: After informed consent was obtained, 5 mm
skin punch biopsies were taken from the forearms of four other
KS patients, who were from two unrelated families. Clinical
and molecular analysis of these patients has been described in
detail by Suzuki et al. and Kliemann et al. [4,18]. Control skin
samples were obtained from two patients that were
undergoing surgery and had no suspicion of KS. Informed
consent was also obtained from these patients. This project
was approved by the Ethical Committee of the Institute of
Biosciences, University of São Paulo (São Paulo, Brazil).
Tissue samples were fixed according to a procedure
described elsewhere [22]. Briefly, samples were immediately
fixed and cryosubstituted in a −70 °C solution of 80%
methanol and 20% dimethyl sulfoxide for 5–7 days,
transferred to −20 °C for 1–2 days, and then brought to room
temperature. Samples were rinsed 3X in absolute ethanol and
embedded in Paraplast Plus following standard protocols. In
addition to maintaining morphological structure, this method
also appears to preserve the antigenicity to a higher degree
than aldehyde fixatives.
Immunofluorescent histochemistry: Xylene was used to
dewax 7 μm-thick sections. These were then rehydrated
through a graded series of ethanol into phosphate-buffered
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4, pH 7.4). Next, 1 mg/ml testicular
hyaluronidase (Sigma, St. Louis, MO) in 50 mM acetate
buffer, pH 5, was added at room temperature for 30 min. This
was followed by several washes in PBS. Blocking was
achieved using 2% BSA (BSA) in PBS at room temperature
for 1 h followed by an overnight incubation at 4 °C with
primary antibodies diluted in PBS containing 0.1% BSA and
0.01% Tween-20. A rabbit polyclonal antibody against type
XVIII collagen (QH48.18, “anti-all”) which recognizes all
three isoforms of type XVIII collagen [23] was used at a
dilution of 1:300. Rabbit anti-human type IV collagen
polyclonal antibody (Rockland, Gilbertsville, PA), an
antibody against type IV collagen, was diluted 1:400 before
it was used as a basement membrane marker. After several
rinses in PBS, sections were incubated for 1 h at room
temperature with 1:300 Cy3-conjugated goat anti-rabbit IgG
secondary antibody (Jackson Laboratory, Bar Harbor, ME).
After several rinses in PBS, sections were mounted in a
mixture of 10% 1.0 M Tris-HCl, pH 9.0 and 90% glycerol and
analyzed using a laser scanning confocal microscope (Zeiss
510META; Carl Zeiss AG, Oberkochen, Germany).
The distribution patterns and levels of expression of types
IV and XVIII collagens were analyzed using pseudocolor
images made with the thermo lookup table in the Confocal
Assistant 4.02 freeware program. This tool utilizes gray-scale
pixel values to generate pseudocolor images that allow the
discrimination of small differences in the level of
immunofluorescence.
Molecular modeling: Human endostatin structure (1BNL)
was obtained from the Protein Data Bank. the p.A1381T
change was created and analyzed using GRASP [24] and
Insight-II/Discover software (Molecular Simulations Inc.,
San Diego, CA).
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Recombinant endostatin production: The coding region of the
endostatin domain was cloned into the pET-15b vector
(Novagen, Madison, WI). p.A1381T endostatin was produced
by PCR-based site directed mutagenesis.
Endostatin production and purification were based on a
procedure published elsewhere [25]. Briefly, recombinant
human endostatin expression in E. coli was induced using
1 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) for 3
h. Cells were isolated by centrifugation and lysed by freeze
thaw cycle in GUMCAC-0-buffer, which contained 6 M
guanidine-HCl, 0.5 M NaCl, and 20 mM Tris-HCl, pH 7.9.
This was followed by sonication in the presence of 15 mM β-
mercaptoethanol. Lysate was loaded onto a ProBond™
column (Invitrogen, Carlsbad, CA) that had been previously
equilibrated with URMCAC-0 buffer, which contained 8 M
urea, 0.5 NaCl, and 20 mM Tris-HCl, pH 7.9. Endostatin was
eluted with a gradient concentration of imidazole (0 to
500 mM) and dialyzed against 4 M urea, 0.1 M NaCl, 1 mM
reduced glutathione, 0.1 mM oxidized glutathione, 20 mM
Tris-HCl pH 7.9 (16 h at 4 °C). This was followed by a dialysis
against 1 M urea, 0.1 M NaCl, 0.1 mM reduced glutathione,
0.01 mM oxidized glutathione, 20 mM Tris-HCl pH 7.9 (6 h
at 4 °C), and a final dialysis step against PBS pH 6.9 (16 h at
4 °C). Human endostatin was then loaded onto a HiTrap-SP
column (Amersham Biosciences, Uppsala, Sweden) and
eluted using a NaCl gradient (0 to 1.5 M) in PBS pH 6.9.
Buffer was exchanged by dialysis against 0.1 M NaCl and
20 mM Tris-HCl (pH 7.4) for 16 h at 4 °C.
Binding assays: Surface plasmon resonance (SPR) assays
were performed with a BIAcore® 3000 instrument (Biacore
AB, Uppsala, Sweden). Extracellular matrix proteins, the
laminin-1-nidogen-1 complex, perlecan, and fibulin were
immobilized on CM5 sensor chips (Biacore AB) as described
previously [26]. Mouse laminin-1-nidogen-1 complex and
mouse perlecan were prepared from the mouse Engelbreth-
Holm-Swarm tumor [27]. The recombinant microfibrillar
component fibulin-1 was prepared following the procedure
published by Sasaki et al. [28]. Binding assays were
performed in triplicates in 0.02 M Tris-HCl, 0.11 M NaCl
containing 0.05% P-20 surfactant (Biacore AB) at a flow rate
of 20 μl/min. The association phase was monitored for 3 min,
and the dissociation curve was recorded for 10 min. The bulk
effects were subtracted using the reference control surfaces.
The chips were regenerated by treatment with 1 M NaCl for
30 s. For the calculation of kinetics constants, the sensorgrams
at concentrations of 0, 10, 50, 200, and 400 nM were fitted
globally to the 1:1 Langmuir model with BIAevaluation
software version 3.1.
ELISA assays were based on a procedure used by Rehn
et al. [25]. Laminin, type IV collagen, nidogen-1, fibulin-1,
and 10 µg/ml heparin-BSA were coated onto the surface of
microtiter wells at 4 °C overnight. All the other steps were
performed at room temperature. The wells were blocked with
5% nonfat milk in 0.05 M Tris-HCl, pH 7.4, 0.11 M NaCl,
2 mM CaCl2, 1 mM MgCl2 (TBS-Ca/Mg) for 1 h and then
washed with 0.05% Tween-20 in TBS-Ca/Mg, and incubated
for 3 h with endostatin as a soluble ligand diluted in 5% nonfat
milk TBS-Ca/Mg. After thoroughly washing, the samples
were incubated for 1 h with the antibody HES.6 against the
human endostatin domain [29] diluted in TBS-Ca/Mg-5%
milk, followed by washing with 0.05% Tween-20 in TBS-Ca/
Mg, and incubation with the secondary antibody conjugated
with horseradish peroxidase. Endostatin bound to the
immobilized proteins was detected by adding 5-
aminosalicylic acid (Sigma) in the presence of 0.01% H2O2.
Detection was performed at 490 nm.
RESULTS
Identification of new mutations in COL18A1 leading to KS:
Mutation screening of the COL18A1 gene was performed in
five KS patients, who were from four unrelated families
(KS14–17). All the patients presented with congenital high
myopia and occipital encephalocele, typical KS phenotypic
characteristics. Three of the families are Brazilian (KS14,
KS16, and KS17) and one is North American (KS15).
We identified four mutations not previously described:
one insertion, two out-of-frame deletions in exons coding the
C-terminal region of the protein, and a splice site mutation.
All of these possibly lead to premature stop codons (Table 1).
The mutation that occurs at the acceptor splice site of intron
7, c.929–2A>G, involves a highly conserved base and is
predicted to disrupt splicing according to computational
analysis (NetGene2 version 2.4 [30]; NNSPLICE version 0.9
[31]). We have detected a mutation in only one of the alleles
in families KS14 and KS15, and these patients may be
compound heterozygotes. Even though the KS16 patient was
initially identified as a homozygous carrier of the mutation c.
3514_3515delCT, we found only her mother harbors this
mutation. Paternity was confirmed with the analysis of five
microsatellite markers (D22S944, S1623, S1638, S1648,
S1709). This patient also appeared homozygous for another
mutation in this exon (c.3570G>A), which is present in the
mother in heterozygosity but it is not present in the father, who
carries only the G allele of this SNP. Therefore, we concluded
that the father carries a deletion of at least exon 41 and the
patient is actually hemizygous for the c.3514_3515delCT
mutation and is a compound heterozygote for mutations in the
COL18A1 gene.
p.A1381T mutation leads to a weaker binding affinity to some
of the ECM proteins: To better understand if the rare
p.A1381T endostatin mutation has the potential to disrupt its
function, we performed ELISA and SPR assays to evaluate
the fragment's ability to bind to other ECM proteins. Our
molecular modeling analysis of the p.A1381T endostatin
suggested that it was possible to accommodate the threonine
side chain in this position (Figure 1). ELISA assays showed
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the binding properties of the p.A1381T endostatin to be
similar to the wild type endostatin, without any significant
differences between them. SPR experiments showed that the
p.A1381T mutation leads to a somewhat weaker binding
affinity to some of the ECM proteins that were tested (Figure
2; Table 2). The differences between wild type and mutant
endostatin binding to laminin-1-nidogen-1 complex and to
fibulin-1 were small but significant (p=0.0017 and p=0.0011,
respectively). Perlecan binding was weak for both p.A1381T
and wild type endostatins and the difference was not
significant.
Skin biopsies from KS patients do not show COL18A1
expression: Null mutations that affect all type XVIII collagen
isoforms must lead to complete lack of the protein. To confirm
the absence of type XVIII collagen and to evaluate the
possibility of distinguishing KS patients from normal
individuals by the analysis of type XVIII collagen in skin
biopsies, we performed fluorescent immunohistochemical
staining for type XVIII collagen in skin biopsies from two KS
individuals carrying the previously described nonsense
mutation c.3277C>T. We observed a complete lack of type
XVIII collagen expression in the tissue sections, while control
samples displayed high levels of staining in the epithelial and
endothelial basement membranes (Figure 3). The lack of
expression of type XVIII collagen was especially evident in
pseudocolor, thermo images in which even minor amounts of
immunofluorescently labeled material can be visualized.
Although another basement membrane protein, type IV
collagen, showed a similar distribution pattern in both control
and KS groups, its immunostaining intensity in KS samples
was noticeably lower (Figure 3).
To understand the cause of KS in individuals carrying the
change p.A1381T we also performed immunohistochemistry
from skin biopsies of two patients. Surprisingly, they also
showed lack of type XVIII collagen staining (Figure 3).
DISCUSSION
KS is thought to be a rare condition: only 42 patients from 15
unrelated families have been described [2,4,5,16-18,20,
32-36]. Among these families, only 12 different COL18A1
mutations have been identified [3-5,15-17]. Although some
clustering has been observed in exon 41, there is heterogeneity
of mutation site distribution. Here we describe four unrelated
families harboring five different mutations (Table 1); all of
the patients are compound heterozygotes. KS16 represents an
unusual case, where the chromosome inherited from the father
has an undetermined deletion in COL18A1 that includes exon
41. This mechanism may elucidate cases already reported
where COL18A1 mutations were not detected [4]. Sequencing
the 43 exons of this gene is laborious for small study centers
to confirm the KS diagnosis, so the identification of biases in
mutation distribution could help in the molecular diagnosis.
Mutations identified so far indicate that exons 30 through 42
of COL18A1 are more frequently mutated, as 5 (83.3%) out
of 6 mutations here identified were located in these exons, as
well as 9 (64.3%) out of 14 previously identified mutations.
Interestingly, 5 (26.3%) out of 19 mutations previously
identified are located in exon 41, pointing to this exon as the
most frequently affected. For this reason, we suggest that
TABLE 1. MUTATIONS IDENTIFIED IN KS PATIENTS.
Patient Mutation Region
Affected
Isoforms
Description of
mutation
KS1 c.12–2A>T (homozygous) Intron 1 Short isoform [3]
KS3 c.2969–2978delCAGGGCCCCC (maternal) Exon 36 All isoforms [4]
c.3514–3515delCT (paternal) Exon 41
KS4 c.1238–1239insA (maternal) Exon 10 All isoforms [4]
c.3514–3513delCT (paternal) Exon 41
KS5 c.3514–3515delCT (maternal) Exon 41 All isoforms [4]
c.2105delT (paternal) Exon 23
KS8 c.12–2A>T (homozygous) Intron 1 Short isoform [4]
KS9 c.3277C>T (homozygous) Exon 40 All isoforms [4]
KS10 c.2416C>T (homozygous) Exon 18 All isoforms [5], [17]
KS11 c.3769G>A (p.D1437N *) (maternal) Exon 42 All isoforms [15]
c.2823_2824insC (paternal) Exon 35
KS12 c.3601G>A (p.A1381T *) (homozygous) Exon 41 All isoforms [18]
KS13 c.3544+3A>C (homozygous) Intron 36 All isoforms [16]
KS14 c.2673_2674insC (heterozygous) Exon 33 All isoforms Novel mutation
KS15 c.2824_2831delGGCCCCCC (heterozygous) Exon 35 All isoforms Novel mutation
KS16 c.3514–3515delCT (maternal) Exon 41 All isoforms Novel mutation
exon 41 deleted (paternal) Novel mutation
KS17 c.2673_2674insC (maternal) Exon 33 All isoforms Novel mutation
c.929–2A>G (paternal) Intron 7 Novel mutation
List of published COL18A1 mutations identified in Knobloch syndrome patients and the exon numbers of the mutation sites.
Asterisk represents position based on the NC11–493 isoform (AF018081.1).
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Figure 1. Molecular modeling of wild type and p.A1381T endostatins. Analysis of the electrostatic surface of wild type (A) and p.A1381T
(B) endostatins. Areas shown in red represent a negative potential while the blue areas are positive. The position 48 of the endostatin domain
(Protein Data Bank entry 1BNL) corresponds to the position 1381 of the NC11–493 isoform (GenBank AF018081.1).
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mutation screening in KS patients should start with these
exons. It is possible that KS is less rare, and the spectrum of
clinical variability is wider than predicted.
To find an additional way to detect type XVIII collagen
disruption in KS patients and gain a deeper understanding of
the KS etiology, we performed protein measurements in situ
and characterization of a mutation with an unknown effect in
vitro. We evaluated for the first time the
immunohistochemical presence of type XVIII collagen in KS
patients. We have analyzed the distribution pattern of type
XVIII collagen in skin biopsies of four KS patients: two
siblings with the known pathogenic nonsense mutation c.
3277C>T and two other siblings with the missense endostatin
mutation c.3601G>A (p.A1381T). As expected for carriers of
null mutations, we were unable to detect type XVIII collagen
in any of the tested KS patients, including those with typical
KS clinical features that harbor the mutation p.A1381T, of
uncertain effect, confirming that the primary molecular defect
is in collagen XVIII. Interestingly, the KS samples also show
a lower expression level of type IV collagen when compared
with the control samples. Since endostatin/collagen XVIII
binds to several ECM components [12-14], it is possible that
Figure 2. SPR sensorgrams of
endostatin interactions with ECM
components. Endostatin variants (wild
type, mutant p.A1381T) were diluted to
a concentration series in 0.02 M Tris-
HCl, 0.11 M NaCl containing 0.05%
P-20, and then injected into the sensor
chips immobilized with laminin-1-
nidogen-1 complex (A=wt,
B=p.A1381T), fibulin (C=wt,
D=p.A1381T), and perlecan (E=wt,
F=p.A1381T) at 25 °C with a flow rate
of 20 μl/min. Sensorgrams show
binding of various concentrations of
endostatin to the coated sensor surfaces.
The association curves were monitored
for 3 min, and the dissociation phases
were recorded for 10 min but presented
for 5 min. All the kinetics studies were
performed three times independently at
concentrations of 0–400 nM, and the
data were analyzed with BIAevaluation
software version 3.1 using the 1:1
Langmuir binding model.
TABLE 2. BINDING AFFINITIES (KD) OF WILD TYPE AND MUTANT ENDOSTATINS TO ECM COMPONENTS
Sample Laminin-1-nidogen-1 complex Fibulin Perlecan
Wild type 3.48±0.24 nM 3.10±0.39 nM 5.53±1.53 nM
p.A1381T 6.17±0.27 nM 6.95±0.25 nM 5.19±0.92 nM
The kinetics constants were obtained by fitting the sensorgrams to the 1:1 Langmuir model.
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a lack of this protein may lead to changes in the overall
organization and stability of the ECM, especially in the
basement membrane where it is normally expressed.
We also tested the p.A1381T endostatin for binding
affinity to a selection of ECM proteins. Even though the
molecular modeling of the protein did not predict a significant
modification, p.A1381T has a weaker affinity to some of the
tested ECM components when compared with wild-type
endostatin. Indeed, Stahl et al. (2005) [19] used a recombinant
human p.A1381T endostatin in a mammalian expression
system and suggested that this change leads to a reduced
folding efficiency. They based this suggestion on the residue
position and the observed 40% reduction in p.A1381T
endostatin production. Considering that KS is probably
caused by a complete disruption of at least the isoform NC11–
303, the current data does not allow us to conclude that the
p.A1381T residue change is sufficient to lead to the KS
phenotype or is pathogenic, but this hypothesis seems
unlikely. Although in silico analysis indicates that the c.
3601G>A change does not create new splice sites (data not
shown), we cannot exclude the possibility that it affects
splicing in vivo and leads to creation of a premature stop
codon, since no type XVIII collagen was detected in the skin
biopsies of these patients. It is also possible that the KS in this
family is caused by a yet to be detected mutation or larger
deletion in COL18A1.
We have previously shown that endostatin serum levels
measured by an ELISA assay were lower in KS patients as
compared with controls [4]. Although we were able to
discriminate patients and controls through this method, we
raised the hypothesis that the antibody used in the assay is
cross-reactive. This is evidenced by the positive endostatin
levels in KS patients that are carriers of null mutations, which
should lead to a complete or nearly complete lack of type
XVIII collagen. The immunohistochemistry results confirm
our prediction that null mutations in the COL18A1 gene lead
Figure 3. Immunofluorescent localization of type XVIII collagen in KS and control skin samples. Differential interference contrast (DIC)
images (A, F, K) show that the epithelial and connective tissues obtained from skin biopsies were intact and well preserved after being prepared
using cryofixation and cryosubstitution techniques. Immunolocalization analyses of KS patients carrying the p.A1381T change (B, C) and
the nonsense mutation c.3277C>T (NC11–493 isoform position p.G1273X, GenBank AF018081.1; G, H) were negative for expression of
collagen XVIII as compared to controls (L, M). Pseudocolor, thermo images showed that collagen XVIII expression was present in control
samples (M) but undetectable in KS samples (C, H). Although the distribution pattern of type IV collagen was similar in both control (N,
O), and KS (D, E, I, J) groups, the immunostaining intensity was noticeably lower in KS samples. The thermo color bar to the right of panel
E indicates immunofluorescence staining intensity: red, higher levels; blue/black, lower levels. Arrows point to basement membrane, and
arrowheads mark blood vessels. Scale bars equal 100 μm.
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to a severe depletion of the protein. Therefore,
immunohistochemical assessment of type XVIII collagen for
diagnosing KS may be more precise than endostatin
measurements through ELISA assays. The mutation
screening of COL18A1 gene is still expensive and laborious,
and the effect of some detected mutations may be uncertain,
as is the case for the endostatin p.A1381T change. Even when
a possible pathogenic mutation is found, the
immunohistochemical analysis of skin biopsies can be an
important tool to confirm the diagnosis. Finally, we show for
the first time that it is possible to diagnose KS through the
direct detection of the protein. In turn, this could allow the
screening of a larger number of patients with a possible
diagnosis of KS and could help in understanding the
phenotypic spectrum of this syndrome.
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